PGN 503Alternative Names: PGN503
Latest Information Update: 05 Jul 2016
At a glance
- Originator Periphagen Holdings
- Mechanism of Action Nerve growth factor receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Peripheral nervous system diseases
Most Recent Events
- 05 Jul 2016 Preclinical trials in Peripheral nervous system diseases (Chemotherapy-induced) in USA (unspecified route) prior to July 2016
- 05 Jul 2016 PGN 503 is available for licensing as of 05 Jul 2016. http://www.periphagen.com/